Inscrivez-vous
Newsroom
Arjo’s interim report January-June 2025
”We are growing in line with our target with double-digit growth in the US, while further strengthening our order book. In parallel, our focused cost efficiency efforts are generating results, and adjusted for currency effects and US tariffs, underlying profitability for the quarter trended positively. We now look forward to a strong net sales...
Freeing up time to focus on what matters most: how Arjo supports better healthcare delivery
In today’s healthcare landscape, time is one of the most valuable and limited resources. As highlighted in a newly published McKinsey report, “Heartbeat of Health”, freeing up time for healthcare professionals is essential to addressing workforce shortages, improving care quality, and ensuring long-term healthcare delivery.
Arjo announces date for 2025 Q2 and conference call
Arjo will issue its interim report for Q2 on Friday July 11 at 07:00 CEST, followed by a conference call at 08:00 CEST, hosted by Niclas Sjöswärd, interim President and CEO, and Christofer Carlsson, interim CFO.
Arjo issues bond under MTN program
Arjo has completed the first issue of SEK 1 billion under the recently established MTN program. The issue received considerable interest from the market and the transaction was quickly oversubscribed.
Arjo establishes MTN program
Arjo AB has established a medium-term note programme with a framework amount of SEK 5 billion.
Resolutions at Arjo’s Annual General Meeting 2025
Arjo AB (publ) held the Annual General Meeting on Tuesday 29 April 2025 in Malmö. At the Annual General Meeting the following was resolved:
Arjo’s interim report January-March 2025
”We are starting the year with growth in line with our target, a strengthened order book and an improved gross margin. Profitability was held back by the stronger SEK, but adjusted for currency, adjusted operating profit increased during the quarter. We remain focused on driving the business and strengthening our long-term competitiveness with new...
Arjo strengthens leading position in patient handling by introducing the new Maxi Move 5 patient floor lift
Arjo, a global leader in medical device technology, today announces the launch of Maxi Move 5[®], the latest generation of one of the company’s best-selling products. The new top-of-the-line mobile patient floor lift features several innovative technical solutions designed to help reduce caregiver injuries and optimize efficiencies in care...
Arjo announces date for 2025 Q1 and conference call
Arjo will issue its interim report for Q1 on Tuesday April 29 at 14:00 CEST, followed by a conference call at 15:00 CEST, hosted by Niclas Sjöswärd, interim President and CEO, and Christofer Carlsson, interim CFO.
Arjo publishes its Annual and Sustainability Report for 2024
Arjo’s Annual and Sustainability Report for 2024 is now available on the Group’s website.
Arjo appoints Eva Brike as new Executive Vice President Human Resources & Sustainability and member of the Arjo Management Team
Arjo has appointed Eva Brike as new EVP Human Resources & Sustainability starting June 1, 2025. Eva succeeds Marion Gullstrand, who after a long operational career has chosen to pursue new opportunities.
NOTICE OF ANNUAL GENERAL MEETING IN ARJO AB (PUBL)
The shareholders of Arjo AB (publ), Corporate ID No. 559092-8064, are hereby invited to attend the Annual General Meeting (the “AGM”) on Tuesday, 29 April 2025 at 5.00 p.m. CEST, at Glasklart, Dockplatsen 1, Malmö, Sweden.
Dawes-Redman CTG Analysis™ receives 510(k) approval from the FDA
Dawes-Redman CTG Analysis™, used for fetal diagnostics, has received 510(k) approval from the U.S. Food and Drug Administration (FDA). Arjo's diagnostics division, Huntleigh Healthcare, has been the exclusive global distributor of the solution for many years, and the approval means it can now be offered to customers also in the US market.
Change in Arjo’s Management Team
Today Arjo announces that Christian Stentoft is leaving his position as President Global Sales & Service and member of the Arjo Management Team.
Arjo’s year-end report January-December 2024
”We close the year with a solid fourth quarter with growth and increased profitability. We have a strong foundation to stand on and enter 2025 with positive momentum in key markets such as the US and UK. In parallel, we remain committed to our efforts for continued profitability improvements moving forward,” says Niclas Sjöswärd, Interim President...
Arjo announces date for 2024 year-end report and conference call
Arjo will issue its year-end report for 2024 on Thursday January 30 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Niclas Sjöswärd, interim President and CEO, and Christofer Carlsson, interim CFO.
Arjo introduces Symbliss – the next-generation integrated bathing system
Arjo, a global leader in medical device technology, is today presenting Symbliss[®], an innovative assisted bathing system setting a new standard in the healthcare industry. Symbliss supports workflows that reduce caregiver injuries, optimize efficiencies in care settings and enables person-centered wellness experiences.
Christofer Carlsson appointed interim CFO at Arjo
Due to Niclas Sjöswärd taking on the role of acting CEO for Arjo following Joacim Lindoff’s departure from the company, Christofer Carlsson has been appointed interim CFO, effective today.
Arjo publishes summary of the result for Q4 2024
In light of this morning’s communication that Joacim Lindoff is leaving his position as CEO of Arjo and to avoid speculation, Arjo is releasing a summary of the year-end report for 2024 before the publication of the complete year-end report on January 30.
Joacim Lindoff leaving position as President & CEO of Arjo
The Board of Directors of Arjo and Joacim Lindoff have come to an agreement which implicates Joacim leaving his position as President & CEO of Arjo, a role he has held since 2017. Niclas Sjöswärd, currently CFO of Arjo, has been appointed interim President & CEO. The process of recruiting a new CEO will be initiated immediately.